Payment overview · 2025
General Payments
$2,095.54
83 reported records · 24 companies
Healthcare provider profile · identity verified
Marvin Dwight Maxwell, MD
Allopathic & Osteopathic Physicians|Family Medicine · SEBRING, FL · NPI 1720001209
Verified facts
What the public records show
CMS Open Payments records show Marvin Dwight Maxwell, MD received $2,095.54 in general payments during 2025 across 83 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 334 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $387.21 | 18.5% | 8 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $233.58 | 11.2% | 15 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $197.23 | 9.4% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $166.05 | 7.9% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $164.57 | 7.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $161.26 | 7.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $154.05 | 7.3% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $150.69 | 7.2% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $69.48 | 3.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.85 | 2.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.82 | 1.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.39 | 1.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.80 | 1.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.01 | 1.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $32.08 | 1.5% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $25.17 | 1.2% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $24.62 | 1.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.56 | 1.2% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $21.88 | 1.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.12 | 1.0% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $18.86 | 0.9% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $17.09 | 0.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.24 | 0.8% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $13.93 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,095.54 | 83 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $250.50 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $233.58 | 15 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $197.23 | 11 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $166.05 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $150.69 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $141.35 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $136.52 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $106.64 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $103.90 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $79.47 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $69.48 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $50.15 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.15 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $50.15 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $45.85 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $41.75 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $40.82 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.20 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.80 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.01 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $32.08 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.22 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 334 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 178 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 95 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 212 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
164 | 51 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
37 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
178 | 44 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 26 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
62 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
212 | 67 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
334 | 106 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
112 | 107 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1828 | 535 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1811 | 554 |
| Amlodipine Besylate | Amlodipine Besylate | 1201 | 359 |
| Lisinopril | Lisinopril | 995 | 304 |
| Omeprazole | Omeprazole | 930 | 286 |
| Losartan Potassium | Losartan Potassium | 919 | 270 |
| Alprazolam | Alprazolam | 878 | 214 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 840 | 256 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 720 | 140 |
| Pantoprazole Sodium | Pantoprazole Sodium | 676 | 216 |
| Gabapentin | Gabapentin | 651 | 225 |
| Metoprolol Succinate | Metoprolol Succinate | 649 | 221 |
| Metformin Hcl | Metformin Hcl | 634 | 200 |
| Tamsulosin Hcl | Tamsulosin Hcl | 618 | 183 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 578 | 100 |
| Tramadol Hcl | Tramadol Hcl | 527 | 154 |
| Clopidogrel | Clopidogrel Bisulfate | 493 | 154 |
| Simvastatin | Simvastatin | 477 | 140 |
| Hydrochlorothiazide | Hydrochlorothiazide | 470 | 156 |
| Furosemide | Furosemide | 465 | 157 |
| Metoprolol Tartrate | Metoprolol Tartrate | 439 | 156 |
| Carvedilol | Carvedilol | 412 | 114 |
| Temazepam | Temazepam | 375 | 89 |
| Eliquis | Apixaban | 334 | 106 |
| Pravastatin Sodium | Pravastatin Sodium | 308 | 81 |
| Lorazepam | Lorazepam | 296 | 82 |
| Escitalopram Oxalate | Escitalopram Oxalate | 293 | 100 |
| Zolpidem Tartrate | Zolpidem Tartrate | 292 | 99 |
| Sertraline Hcl | Sertraline Hcl | 289 | 81 |
| Trazodone Hcl | Trazodone Hcl | 277 | 88 |
| Montelukast Sodium | Montelukast Sodium | 258 | 84 |
| Potassium Chloride | Potassium Chloride | 251 | 89 |
| Mounjaro | Tirzepatide | 250 | 50 |
| Meloxicam | Meloxicam | 236 | 87 |
| Ozempic | Semaglutide | 212 | 67 |
| Famotidine | Famotidine | 210 | 75 |
| Ezetimibe | Ezetimibe | 208 | 63 |
| Oxycodone Hcl | Oxycodone Hcl | 190 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 77 |
| Atenolol | Atenolol | 183 | 60 |
| Allopurinol | Allopurinol | 182 | 60 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 181 | 150 |
| Duloxetine Hcl | Duloxetine Hcl | 181 | 60 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 179 | 80 |
| Farxiga | Dapagliflozin Propanediol | 178 | 44 |
| Clonazepam | Clonazepam | 175 | 45 |
| Finasteride | Finasteride | 175 | 50 |
| Prednisone | Prednisone | 172 | 92 |
| Synthroid | Levothyroxine Sodium | 164 | 51 |
| Azithromycin | Azithromycin | 163 | 137 |
| Celecoxib | Celecoxib | 160 | 58 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 151 | 43 |
| Alendronate Sodium | Alendronate Sodium | 150 | 42 |
| Pregabalin | Pregabalin | 150 | 32 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 150 | 117 |
| Ropinirole Hcl | Ropinirole Hcl | 145 | 41 |
| Estradiol | Estradiol | 143 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 134 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 131 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 129 | 43 |
| Memantine Hcl | Memantine Hcl | 128 | 47 |
| Bupropion Xl | Bupropion Hcl | 122 | 39 |
| Donepezil Hcl | Donepezil Hcl | 122 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 122 | 44 |
| Diazepam | Diazepam | 121 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 45 |
| Metformin Hcl Er | Metformin Hcl | 117 | 45 |
| Paxlovid | Nirmatrelvir/Ritonavir | 112 | 107 |
| Spironolactone | Spironolactone | 111 | 38 |
| Baclofen | Baclofen | 109 | 26 |
| Xarelto | Rivaroxaban | 107 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 106 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 105 | 37 |
| Glimepiride | Glimepiride | 99 | 38 |
| Valsartan | Valsartan | 98 | 32 |
| Benazepril Hcl | Benazepril Hcl | 97 | 26 |
| Eszopiclone | Eszopiclone | 95 | 29 |
| Jardiance | Empagliflozin | 95 | 26 |
| Testosterone Cypionate | Testosterone Cypionate | 91 | 31 |
| Lovastatin | Lovastatin | 89 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 89 | 60 |
| Glipizide | Glipizide | 87 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 30 |
| Bumetanide | Bumetanide | 80 | 28 |
| Warfarin Sodium | Warfarin Sodium | 77 | 22 |
| Fenofibrate | Fenofibrate | 76 | 22 |
| Myrbetriq | Mirabegron | 76 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 75 | 32 |
| Cephalexin | Cephalexin | 73 | 55 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 70 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 23 |
| Morphine Sulfate Er | Morphine Sulfate | 64 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 64 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 21 |
| Entresto | Sacubitril/Valsartan | 62 | 22 |
| Dutasteride | Dutasteride | 61 | 17 |
| Meclizine Hcl | Meclizine Hcl | 61 | 27 |
| Enalapril Maleate | Enalapril Maleate | 60 | 20 |
| Fluconazole | Fluconazole | 60 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 19 |
| Nitroglycerin | Nitroglycerin | 59 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 32 |
| Bupropion Hcl Sr | Bupropion Hcl | 58 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 54 |
| Chlorthalidone | Chlorthalidone | 57 | 19 |
| Ibuprofen | Ibuprofen | 57 | 27 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | 17 |
| Buspirone Hcl | Buspirone Hcl | 56 | 21 |
| Amoxicillin | Amoxicillin | 55 | 51 |
| Topiramate | Topiramate | 54 | 15 |
| Mirtazapine | Mirtazapine | 52 | 21 |
| Propranolol Hcl | Propranolol Hcl | 52 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 49 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 14 |
| Clonidine Hcl | Clonidine Hcl | 48 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 38 |
| Primidone | Primidone | 47 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | 14 |
| Trulicity | Dulaglutide | 46 | 12 |
| Methylprednisolone | Methylprednisolone | 45 | 36 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | 15 |
| Glipizide Er | Glipizide | 43 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 14 |
| Fentanyl | Fentanyl | 42 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 18 |
| Sucralfate | Sucralfate | 42 | 11 |
| Hydromorphone Hcl | Hydromorphone Hcl | 41 | suppressed |
| Ramipril | Ramipril | 40 | 11 |
| Metolazone | Metolazone | 38 | 14 |
| Terazosin Hcl | Terazosin Hcl | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | 11 |
| Prolia | Denosumab | 37 | 24 |
| Venlafaxine Hcl | Venlafaxine Hcl | 37 | 11 |
| Levetiracetam | Levetiracetam | 35 | 12 |
| Ondansetron Odt | Ondansetron | 35 | 24 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 35 | 34 |
| Hydrocortisone | Hydrocortisone | 34 | 17 |
| Verapamil Er | Verapamil Hcl | 34 | 13 |
| Valacyclovir | Valacyclovir Hcl | 33 | 20 |
| Liothyronine Sodium | Liothyronine Sodium | 32 | suppressed |
| Naproxen | Naproxen | 32 | 13 |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Testosterone | Testosterone | 31 | 13 |
| Acyclovir | Acyclovir | 30 | 13 |
| Anastrozole | Anastrozole | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 30 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Metronidazole | Metronidazole | 28 | 16 |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 28 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 28 | 11 |
| Cilostazol | Cilostazol | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 23 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 18 |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | 11 |
| Kerendia | Finerenone | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Qulipta | Atogepant | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Klor-Con 10 | Potassium Chloride | 18 | suppressed |
| Livalo | Pitavastatin Calcium | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 18 | suppressed |
| Verapamil Sr | Verapamil Hcl | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Methadone Hcl | Methadone Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 13 |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Zaleplon | Zaleplon | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Restoril | Temazepam | 12 | suppressed |
| Toprol Xl | Metoprolol Succinate | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,095.54 · 83 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CREON, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, Leqembi, NEXLETOL, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PREVNAR 20, QUTENZA, RECORLEV, REPATHA, REXULTI, SHINGRIX, SMARTVEST, TONMYA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, XYOSTED, ZAVZPRET, t:slim X2 Insulin Pump with Control-IQ | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error